MUMBAI (Reuters) - Drugmaker Cadila Healthcare Ltd received regulatory approval to market a new diabetes drug in India that it developed and is aiming for more than $1 billion in sales globally, the company said on Wednesday. Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India, the company's chairman, Pankaj Patel, said. ... Get the complete story
No comments:
Post a Comment